VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, [3], 4 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 12:32:09 02/02/00 Wed
Author: warren
Subject: Check this out...

Printing 1.375 x 1.4375

Picked up some shares at 1.4375.Low volume!

Wednesday February 2, 12:20 pm Eastern Time

Company Press Release

Lexon Acquires Exclusive Rights to Blood Test for
Lung Cancer

TULSA, Okla.--(BW HealthWire)--Feb. 2, 2000--Lexon, Inc. (OTC:LXXN - news) today announced that it has acquired
the exclusive worldwide rights to the Telomerase Assay, a patent-pending blood test for lung cancer, by way of purchasing
100% of the common stock of Cancer Diagnostic, Inc. (``CDI'').

The purchase of CDI for a total of $200,000 in cash and notes was made in lieu of the previously announced merger of CDI
into Lexon and eliminates the requirement under the merger agreement for Lexon to issue 500,000 shares of its common stock
to CDI.

The Telomerase Assay evolved from research performed at the University of Maryland, Baltimore Medical Center by a team
under the direction of Dr. Edward Highsmith. He and his team will continue to oversee the Lexon-sponsored development and
commercialization of the test for the ELISA format, and subsequent FDA submission. Dr. Highsmith recently received funding
in the amount of $1.1 million from the National Institutes of Health to study telomerase in lung cancer patients. The funding will
support the gathering of clinical data on the Telomerase Assay. Lung cancer is the leading cause of cancer deaths worldwide.

Lexon also owns the exclusive worldwide rights to the Ebaf Assay(tm), a blood test for colon cancer screening. Dr. Siamak
Tabibzadeh is developing the test at North Shore University Hospital in Manhasset, New York. Lexon recently announced the
production and successful characterization of a polyclonal antibody to the ebaf protein. Current efforts are focused on
producing and characterizing a monoclonal antibody to the ebaf protein which, once completed, will allow for the production of
an ELISA prototype colon cancer screening test. Colon cancer is the second leading cause of cancer deaths.

This press release contains some forward-looking statements. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in
this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are
discussed in the Company's SEC filings.

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Replies:

[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.